173 related articles for article (PubMed ID: 30026381)
1. Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer.
Buechel M; Dey A; Dwivedi SKD; Crim A; Ding K; Zhang R; Mukherjee P; Moore KN; Cao L; Branstrom A; Weetall M; Baird J; Bhattacharya R
Mol Cancer Ther; 2018 Oct; 17(10):2136-2143. PubMed ID: 30026381
[TBL] [Abstract][Full Text] [Related]
2. BMI‑1 promotes invasion and metastasis in endometrial adenocarcinoma and is a poor prognostic factor.
Yu J; Chen L; Bao Z; Liu Y; Liu G; Li F; Li L
Oncol Rep; 2020 May; 43(5):1630-1640. PubMed ID: 32323819
[TBL] [Abstract][Full Text] [Related]
3. Targeting Interleukin-11 Receptor-α Impairs Human Endometrial Cancer Cell Proliferation and Invasion In Vitro and Reduces Tumor Growth and Metastasis In Vivo.
Winship AL; Van Sinderen M; Donoghue J; Rainczuk K; Dimitriadis E
Mol Cancer Ther; 2016 Apr; 15(4):720-30. PubMed ID: 26846819
[TBL] [Abstract][Full Text] [Related]
4. Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma.
Theisen ER; Gajiwala S; Bearss J; Sorna V; Sharma S; Janat-Amsbury M
BMC Cancer; 2014 Oct; 14():752. PubMed ID: 25300887
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer.
Dey A; Xiong X; Crim A; Dwivedi SKD; Mustafi SB; Mukherjee P; Cao L; Sydorenko N; Baiazitov R; Moon YC; Dumble M; Davis T; Bhattacharya R
Mol Cancer Ther; 2018 Jan; 17(1):39-49. PubMed ID: 29158468
[TBL] [Abstract][Full Text] [Related]
6. The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells.
Mayr C; Wagner A; Loeffelberger M; Bruckner D; Jakab M; Berr F; Di Fazio P; Ocker M; Neureiter D; Pichler M; Kiesslich T
Oncotarget; 2016 Jan; 7(1):745-58. PubMed ID: 26623561
[TBL] [Abstract][Full Text] [Related]
7.
Ganaie AA; Beigh FH; Astone M; Ferrari MG; Maqbool R; Umbreen S; Parray AS; Siddique HR; Hussain T; Murugan P; Morrissey C; Koochekpour S; Deng Y; Konety BR; Hoeppner LH; Saleem M
Clin Cancer Res; 2018 Dec; 24(24):6421-6432. PubMed ID: 30087142
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of Bmi1 inhibits bladder cancer cell growth both in vitro and in vivo by blocking cell cycle at G1 phase and inducing apoptosis.
Luo HB; Li B; Yuan WG; Xu CR
J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):730-735. PubMed ID: 26489630
[TBL] [Abstract][Full Text] [Related]
9. A genome-wide enrichment screen identifies NUMA1-loss as a resistance mechanism against mitotic cell-death induced by BMI1 inhibition.
Gisler S; Maia ARR; Chandrasekaran G; Kopparam J; van Lohuizen M
PLoS One; 2020; 15(4):e0227592. PubMed ID: 32343689
[TBL] [Abstract][Full Text] [Related]
10. Alantolactone inhibits cervical cancer progression by downregulating BMI1.
Sun X; Xu H; Dai T; Xie L; Zhao Q; Hao X; Sun Y; Wang X; Jiang N; Sang M
Sci Rep; 2021 Apr; 11(1):9251. PubMed ID: 33927214
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma.
Bartucci M; Hussein MS; Huselid E; Flaherty K; Patrizii M; Laddha SV; Kui C; Bigos RA; Gilleran JA; El Ansary MMS; Awad MAM; Kimball SD; Augeri DJ; Sabaawy HE
Target Oncol; 2017 Aug; 12(4):449-462. PubMed ID: 28589491
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of Bmi1 in breast cancer stem cells suppresses tumor growth and proliferation.
Srinivasan M; Bharali DJ; Sudha T; Khedr M; Guest I; Sell S; Glinsky GV; Mousa SA
Oncotarget; 2017 Jun; 8(24):38731-38742. PubMed ID: 28418883
[TBL] [Abstract][Full Text] [Related]
13. Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy.
Griffith J; Andrade D; Mehta M; Berry W; Benbrook DM; Aravindan N; Herman TS; Ramesh R; Munshi A
Oncol Rep; 2017 Apr; 37(4):2382-2390. PubMed ID: 28260023
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
Makker V; Hensley ML; Zhou Q; Iasonos A; Aghajanian CA
Int J Gynecol Cancer; 2013 Jun; 23(5):929-34. PubMed ID: 23598889
[TBL] [Abstract][Full Text] [Related]
15. CSC-3436 inhibits TWIST-induced epithelial-mesenchymal transition via the suppression of Twist/Bmi1/Akt pathway in head and neck squamous cell carcinoma.
Lai YJ; Yu WN; Kuo SC; Ho CT; Hung CM; Way TD; Chen CT
J Cell Physiol; 2019 Jun; 234(6):9118-9129. PubMed ID: 30341909
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of BMI1 induces autophagy-mediated necroptosis.
Dey A; Mustafi SB; Saha S; Kumar Dhar Dwivedi S; Mukherjee P; Bhattacharya R
Autophagy; 2016; 12(4):659-70. PubMed ID: 27050456
[TBL] [Abstract][Full Text] [Related]
17. PTC209, a Specific Inhibitor of BMI1, Promotes Cell Cycle Arrest and Apoptosis in Cervical Cancer Cell Lines.
Li J; Vangundy Z; Poi M
Anticancer Res; 2020 Jan; 40(1):133-141. PubMed ID: 31892561
[TBL] [Abstract][Full Text] [Related]
18. Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma.
Proctor E; Waghray M; Lee CJ; Heidt DG; Yalamanchili M; Li C; Bednar F; Simeone DM
PLoS One; 2013; 8(2):e55820. PubMed ID: 23437065
[TBL] [Abstract][Full Text] [Related]
19. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.
Teshima K; Nara M; Watanabe A; Ito M; Ikeda S; Hatano Y; Oshima K; Seto M; Sawada K; Tagawa H
Oncogene; 2014 Apr; 33(17):2191-203. PubMed ID: 23686310
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
Bonazzoli E; Predolini F; Cocco E; Bellone S; Altwerger G; Menderes G; Zammataro L; Bianchi A; Pettinella F; Riccio F; Han C; Yadav G; Lopez S; Manzano A; Manara P; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Schlessinger J; Santin AD
Clin Cancer Res; 2018 Oct; 24(19):4845-4853. PubMed ID: 29941483
[No Abstract] [Full Text] [Related]
[Next] [New Search]
